Reports Q3 revenue $153.3M, consensus $154.45M. “We are pleased with our strong performance in the third quarter, growing revenue 40% year-over-year. Our growth continues to be driven primarily by higher utilization at existing sites and was complemented by the addition of 62 new implanting centers and 13 new U.S. sales territories,” said Tim Herbert, President, and Chief Executive Officer of Inspire Medical Systems. “During the quarter, we achieved several important milestones, including surpassing 50,000 patients implanted with Inspire therapy and we also made significant progress with market access by expanding coverage policies with several large national health plans to include our recently expanded indications.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Inspire Medical price target lowered to $250 from $350 at Stifel
- LivaNova price target lowered to $62 from $71 at Needham
- Inspire Medical price target lowered to $180 from $355 at BofA
- Inspire Medical price target lowered to $300 from $380 at Mizuho
- Inspire Medical initiated with a Market Perform at Leerink